Brokerages Set Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Price Target at $10.80

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) has been given an average rating of “Moderate Buy” by the seven analysts that are presently covering the stock, MarketBeat Ratings reports. Three analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $10.80.

Separately, Weiss Ratings upgraded Xeris Biopharma from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, July 23rd.

Insider Transactions at Xeris Biopharma

In related news, insider Kevin Mcculloch sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $8.02, for a total transaction of $120,300.00. Following the transaction, the insider owned 1,676,126 shares in the company, valued at $13,442,530.52. This trade represents a 0.89% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director John Johnson sold 15,000 shares of Xeris Biopharma stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $6.09, for a total value of $91,350.00. Following the transaction, the director directly owned 683,083 shares in the company, valued at approximately $4,159,975.47. This trade represents a 2.15% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 266,499 shares of company stock worth $1,996,417. Insiders own 4.35% of the company’s stock.

Hedge Funds Weigh In On Xeris Biopharma

A number of institutional investors have recently modified their holdings of the business. UBS Group AG raised its position in Xeris Biopharma by 682.4% in the 3rd quarter. UBS Group AG now owns 1,782,734 shares of the company’s stock valued at $14,511,000 after purchasing an additional 1,554,869 shares during the last quarter. Vanguard Group Inc. grew its position in Xeris Biopharma by 13.8% during the 4th quarter. Vanguard Group Inc. now owns 11,186,677 shares of the company’s stock worth $87,815,000 after purchasing an additional 1,358,760 shares during the last quarter. Qube Research & Technologies Ltd grew its position in Xeris Biopharma by 67.5% during the 2nd quarter. Qube Research & Technologies Ltd now owns 3,089,771 shares of the company’s stock worth $14,429,000 after purchasing an additional 1,245,188 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in Xeris Biopharma by 75.4% in the first quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock valued at $15,317,000 after purchasing an additional 1,199,435 shares during the period. Finally, Granahan Investment Management LLC increased its stake in Xeris Biopharma by 249.4% in the fourth quarter. Granahan Investment Management LLC now owns 1,223,404 shares of the company’s stock valued at $9,604,000 after purchasing an additional 873,236 shares during the period. 42.75% of the stock is owned by institutional investors and hedge funds.

Xeris Biopharma Price Performance

Shares of NASDAQ:XERS opened at $8.19 on Friday. The company’s fifty day moving average price is $7.59 and its 200 day moving average price is $6.79. Xeris Biopharma has a 12 month low of $5.25 and a 12 month high of $10.08. The company has a debt-to-equity ratio of 17.00, a current ratio of 2.12 and a quick ratio of 1.50. The firm has a market capitalization of $1.41 billion, a P/E ratio of 136.50 and a beta of 0.66.

Xeris Biopharma (NASDAQ:XERS) last announced its quarterly earnings results on Thursday, May 7th. The company reported $0.01 earnings per share for the quarter. Xeris Biopharma had a net margin of 3.81% and a return on equity of 735.00%. The firm had revenue of $83.13 million during the quarter, compared to analysts’ expectations of $79.83 million. As a group, sell-side analysts predict that Xeris Biopharma will post 0.12 earnings per share for the current fiscal year.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.